Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia

Area of Science:

• Biochemistry
• Clinical Medicine
• Nutritional Science

Background:

• Hyperhomocysteinaemia, affecting ~5% of the population, stems from genetic enzyme defects or vitamin deficiencies (B12, B6, folate).
• Elevated homocysteine levels significantly elevate risks for arterial and venous thromboembolic events.
• Renal impairment is a notable cause of secondary hyperhomocysteinaemia.

Purpose of the Study:

• To review the therapeutic strategies for managing hyperhomocysteinaemia.
• To evaluate the efficacy of folic acid and related vitamin supplementation in lowering homocysteine levels.
• To explore the specific treatment considerations for patients with renal impairment.

Main Methods:

• Literature review of studies investigating homocysteine metabolism and its clinical implications.
• Analysis of data on the effectiveness of folic acid, vitamin B12, and vitamin B6 in reducing homocysteine levels.
• Examination of treatment outcomes in patient groups with varying causes of hyperhomocysteinaemia, including renal disease.

Main Results:

• Folic acid (≥0.4 mg/day) is the primary treatment, effectively lowering homocysteine even in non-deficient individuals.
• Combined supplementation with vitamins B12 and/or B6 may offer marginal additional homocysteine reduction in specific patient cohorts.
• Patients with renal impairment often necessitate higher folic acid doses (5-40 mg) for optimal homocysteine reduction.

Conclusions:

• Folic acid is the cornerstone therapy for hyperhomocysteinaemia.
• Vitamin B12 and B6 supplementation can provide adjunctive benefits.
• Effective homocysteine lowering's impact on vascular disease reduction is under ongoing investigation in prospective trials.